About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
E
2024 Updates in Myeloproliferative Neoplasms
By
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
FEATURING
Elizabeth Hexner
By
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
FEATURING
Elizabeth Hexner
259 views
March 3, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
37:21
Amgen Sponsorship
New Approval for Frontline Consolidation in Patients with CD19-posit…
Feat.
J. Mccloskey
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
08:44
American Contact Dermatitis Society (ACDS)
What to Do When Patch Testing is Negative?
Feat.
M. Montanez-Wiscovich
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
22:21
Integrity CE
2024 Updates on Myeloproliferative Neoplasms, PV, and ET
Feat.
A. Tefferi
06:18
Cleveland Clinic Taussig Cancer Institute
SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…
Feat.
A. Gerds
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
18:42
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
Feat.
A. Goldberg
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
24:48
Indy Hematology Review
2024 Updates on Myelofibrosis and Systemic Mastocytosis
Feat.
R. Rampal
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
17:23
Vanderbilt University Medical Center (VUMC)
Management of MF After Ruxolitinib Failure
Feat.
A. Kishtagari
08:11
Krisstina Gowin
Counseling Patients With Newly Diagnosed PV or ET
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
